DNX-2401: Clinical Trials

3 trials of DNX-2401, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 completed. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Recruiting 2, Completed 1

Follow DNX-2401: new trials by email Literature Review of DNX-2401 trials Research Report on DNX-2401

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
DNX-2401 - High Grade Glioma, Ependymoma
Phase 2RecruitingClinica Universidad de Navarra, Universidad de Navarra392026-05-122026-05-27
Combination Therapy for the Treatment of Diffuse Midline Gliomas
ONC201, Radiation Therapy, Paxalisib - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Phase 2RecruitingUniversity of California, San Francisco3602021-10-202026-06-26
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
DNX-2401, pembrolizumab - Brain Cancer, Brain Neoplasm
Phase 2CompletedDNAtrix, Inc.492016-10-062021-07-15

Conditions studied

Glioma (2)  ·  Brain Neoplasms (1)  ·  Diffuse Intrinsic Pontine Glioma (1)  ·  Disease (1)  ·  Ependymoma (1)  ·  Glioblastoma (1)  ·  Gliosarcoma (1)  ·  Neoplasms (1)  ·  Neoplasms, Nerve Tissue (1)  ·  Neoplasms, Neuroepithelial (1)  ·  Nervous System Diseases (1)  ·  Neuroectodermal Tumors (1)  ·  Recurrence (1)

Sponsors

Clinica Universidad de Navarra, Universidad de Navarra (1)  ·  DNAtrix, Inc. (1)  ·  University of California, San Francisco (1)

Countries

Netherlands (2)  ·  United States (2)  ·  Australia (1)  ·  Canada (1)  ·  Israel (1)  ·  New Zealand (1)  ·  Spain (1)  ·  Switzerland (1)

Top investigators

Nancy Gady, BS (1)  ·  Sabine Mueller, MD, PhD (1)

Results publications

PMID 35157764, PMID 37188783, PMID 37195023

NIH funding

R01NS124607 (1)